Brian D Lehmann

List of Publications by Year in Descending Order

61 papers	9,294 citations	34 h-index	67 g-index
67 ext. papers	10,925 ext. citations	7.2 avg, IF	5.91 L-index

#	Paper	IF	Citations
61	Abstract PD3-04: Multi-omics characterization of triple-negative breast cancer identifies therapeutic vulnerabilities and epigenetic immune suppression in the mesenchymal subtype. *Cancer Research*, **2022**, 82, PD3-04-PD3-04	10.1	
60	Abstract P5-09-01: Using isogenic model systems to determine mechanisms regulating mutant p53 protein stability in breast cancer cells. *Cancer Research*, **2022**, 82, P5-09-01-P5-09-01	10.1	
59	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. *Nature Communications*, **2021**, 12, 6276	17.4	10
58	Tissue-specific expression of p73 and p63 isoforms in human tissues. *Cell Death and Disease*, **2021**, 12, 745	9.8	0
57	LR Hunting: A Random Forest Based Cell-Cell Interaction Discovery Method for Single-Cell Gene Expression Data. *Frontiers in Genetics*, **2021**, 12, 708835	4.5	1
56	Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. *Nature Communications*, **2021**, 12, 5184	17.4	5
55	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. *Science Translational Medicine*, **2020**, 12,	17.5	22
54	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer. *Clinical Cancer Research*, **2020**, 26, 2111-2123	12.9	41
53	Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. *PLoS ONE*, **2020**, 15, e0231711	3.7	5
52	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. *Molecular Cancer Research*, **2019**, 17, 1842-1853	6.6	7
51	Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility. *Oncotarget*, **2019**, 10, 133-151	3.3	5
50	The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. *Genes*, **2018**, 9,	4.2	14
49	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. *Clinical Cancer Research*, **2017**, 23, 4035-4045	12.9	79
48	Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. *BMC Cancer*, **2017**, 17, 241	4.8	20
47	The Utilization of Formalin Fixed-Paraffin-Embedded Specimens in High Throughput Genomic Studies. *International Journal of Genomics*, **2017**, 2017, 1926304	2.5	44
46	Estimating relative mitochondrial DNA copy number using high throughput sequencing data. *Genomics*, **2017**, 109, 457-462	4.3	13
45	Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data. *Briefings in Bioinformatics*, **2016**, 17, 224-32	13.4	23

44	Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. *BMC Cancer*, **2016**, 16, 143	4.8	42
43	RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining. *International Journal of Genomics*, **2016**, 2016, 9837310	2.5	14
42	Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. *PLoS ONE*, **2016**, 11, e0157368	3.7	590
41	Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. *Cancer Research*, **2016**, 76, 4850-60	10.1	28
40	Clinical implications of molecular heterogeneity in triple negative breast cancer. *Breast*, **2015**, 24 Suppl 2, S36-40	3.6	76
39	Practicality of identifying mitochondria variants from exome and RNAseq data. *BMC Bioinformatics*, **2015**, 16, P6	3.6	3
38	RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library. *BioMed Research International*, **2015**, 2015, 862130	3	26
37	Triple-negative breast cancer: molecular subtypes and new targets for therapy. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, e31-9	7.1	83
36	Subtyping of triple-negative breast cancer: implications for therapy. *Cancer*, **2015**, 121, 8-16	6.4	212
35	A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. *PLoS ONE*, **2015**, 10, e0125482	3.7	76
34	Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. *Oncotarget*, **2015**, 6, 21353-68	3.3	31
33	Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. *Journal of Pathology*, **2014**, 232, 142-50	9.4	267
32	New strategies for triple-negative breast cancer--deciphering the heterogeneity. *Clinical Cancer Research*, **2014**, 20, 782-90	12.9	210
31	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. *Breast Cancer Research*, **2014**, 16, 406	8.3	199
30	Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. *Cancer Research*, **2014**, 74, 3180-94	10.1	76
29	Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. *Cancer Discovery*, **2014**, 4, 232-45	24.4	310
28	Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. *Breast Cancer Research*, **2014**, 16, R69	8.3	37
27	Detection of internal exon deletion with exon Del. *BMC Bioinformatics*, **2014**, 15, 332	3.6	10

26	Multi-perspective quality control of Illumina exome sequencing data using QC3. *Genomics*, **2014**, 103, 323-8	4.3	61
25	Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. *Clinical Cancer Research*, **2013**, 19, 2723-33	12.9	119
24	Patient-derived breast tumor xenografts facilitating personalized cancer therapy. *Breast Cancer Research*, **2013**, 15, 201	8.3	69
23	SPARCL1 suppresses metastasis in prostate cancer. *Molecular Oncology*, **2013**, 7, 1019-30	7.9	23
22	Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. *BioMed Research International*, **2013**, 2013, 915636	3	36
21	BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. *Clinical Cancer Research*, **2013**, 19, 6696-702	12.9	122
20	Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. *Clinical Cancer Research*, **2013**, 19, 5533-40	12.9	476
19	A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. *PLoS ONE*, **2013**, 8, e54979	3.7	4
18	Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer.. *Journal of Clinical Oncology*, **2013**, 31, 1005-1005	2.2	5
17	TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. *Cancer Informatics*, **2012**, 11, 147-56	2.4	161
16	p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. *Cell Cycle*, **2012**, 11, 4579-88	4.7	73
15	Targeting mutant p53 in human tumors. *Journal of Clinical Oncology*, **2012**, 30, 3648-50	2.2	59
14	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *Journal of Clinical Investigation*, **2011**, 121, 2750-67	15.9	3125
13	Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. *Oncotarget*, **2011**, 2, 610-26	3.3	38
12	Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2. *American Journal of Physiology - Heart and Circulatory Physiology*, **2010**, 298, H1088-95	5.2	34
11	RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. *Breast Cancer Research*, **2010**, 12, R41	8.3	58
10	Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. *Oncogene*, **2008**, 27, 4086-95	9.2	128
9	Senescence-associated exosome release from human prostate cancer cells. *Cancer Research*, **2008**, 68, 7864-71	10.1	310

8	Targeting prostate cancer based on signal transduction and cell cycle pathways. *Cell Cycle*, **2008**, 7, 1745-62	4.7	80
7	Distinct roles for p107 and p130 in Rb-independent cellular senescence. *Cell Cycle*, **2008**, 7, 1262-8	4.7	15
6	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. *Advances in Enzyme Regulation*, **2008**, 48, 113-35		20
5	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy **2008**, 81-114		
4	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2007**, 1773, 1263-84	4.9	1532
3	Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. *Advances in Enzyme Regulation*, **2007**, 47, 64-103		63
2	A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. *Cell Cycle*, **2007**, 6, 595-605	4.7	80
1	Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. *Cancer Biology and Therapy*, **2007**, 6, 1165-70	4.6	12